Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers

The goal of this clinical trial investigation is to evaluate the tolerance of the T10070 on healthy volunteers by clinical examination under ophthalmological control.Participants will attend 2 visits (inclusion at day 0 and follow-up/final at D7/D9. After inclusion, subjects will have to apply T10070 6 times a day during 7 to 9 days. The following tasks will be asked to participants:ophtalmological examinationdiary completion to record T10070 applications, potential discomfort/reactions observed and medication taken.complete subject questionnaire about usability of the product

Inclusion Criteria:Informed consent signed and datedSubject ≥ 18 years oldHealthy volunteerNormal ocular examination in both eyesNormal skin examination in both eyesMain Exclusion Criteria:Far best-corrected visual acuity (BCVA) ≥ +0.1 LogMar (e.g., ≤ 0.8 in decimal value or ≤ 80/100 Snellen equivalent)Known or suspected hypersensitivity to one of the components of the T10070History of trauma, infection, clinically significant inflammation within the 3 previous monthsOngoing or know history of ocular allergy and/or uveitis and/or viral infectionDiagnosed keratoconusAny palpebral abnormality